Company
Currus Biologics
Unlocking CAR T-cell therapy for solid tumours
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Currus Biologics is developing its proprietary BEAT technology for solid tumours. The BEAT platform unlocks CAR T-cell therapy for solid tumours – approximately 90% of the oncology market, which has remained largely impervious to treatment with current CAR T-cell approaches.
Products
- Web
- BEAT
Loading relationship preview